All In Biotech

Drug Trial Radar · NCT05526066

Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

8

Actual

Start

Oct 17, 2022

Primary completion

Oct 31, 2024

Study completion Oct 31, 2024

Sponsor

Lead sponsor
Arcturus Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the safety and tolerability of repeated doses of intravenously administered ARCT-810.

Conditions

  • Ornithine Transcarbamylase Deficiency
  • OTC Deficiency
  • OTCD

Interventions

  • ARCT-810Biological

    ARCT-810 is messenger RNA (mRNA) coding for Ornithine Transcarbamylase (OTC) formulated in a lipid nanoparticle (LNP).

  • PlaceboOther

    Normal Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity and dose-relationship of adverse events (AEs)Time frame: Week 23

Locations

14 sites in 6 countries. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Hôpitaux Universitaires de Marseille - Hôpital de la Timone

    Marseille, France

  • Assistance Publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker-Enfants Malades

    Paris, France

  • Azienda Ospedaliera di Padova

    Padova, Italy

  • IRCCS Ospedale Pediatrico Bambino Gesu

    Rome, Italy

  • Hospital Clínic de Barcelona

    Barcelona, Spain

  • Hospital Sant Joan de Déu

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Complejo Hospitalario Universitario de Santiago (CHUS) - Hospital Clínico Universitario

    Santiago de Compostela, Spain

  • Karolinska Universitetssjukhuset - Astrid Lindgrens Barnsjukhus

    Stockholm, Sweden

  • University College London Hospitals NHS Foundation Trust - National Hospital for Neurology and Neurosurgery

    London, United Kingdom

  • Salford Royal NHS Foundation Trust - Salford Royal Hospital

    Salford, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital Birmingham

    Birmingham, UK, United Kingdom

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, UK, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.